Cell Entry of C3 Exoenzyme from Clostridium botulinum

被引:7
|
作者
Rohrbeck, Astrid [1 ]
Just, Ingo [1 ]
机构
[1] Hannover Med Sch, Dept Pharmacol & Toxicol, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源
关键词
BINDING PROTEIN-RHO; INTERMEDIATE-FILAMENT CYTOSKELETON; CLATHRIN-INDEPENDENT ENDOCYTOSIS; MICROVASCULAR ENDOTHELIAL-CELLS; IN-VIVO PHOSPHORYLATION; ADP-RIBOSYLATION; SURFACE VIMENTIN; CHOLERA-TOXIN; TAT PROTEIN; STAPHYLOCOCCUS-AUREUS;
D O I
10.1007/82_2016_44
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Clostridium botulinum C3 is the prototype of C3-like ADP-ribosyltransferases that selectively ADP-ribosylate the small GTP-binding proteins RhoA/B/C and inhibit their downstream signaling pathways. It is used as pharmacological tool to study cellular Rho functions. In addition, C3bot harbors a transferase-independent activity on neurons to promote axonal and dendritic growth and branching. Many bacterial protein toxins interact specifically with proteins and/or other membrane components at the surface of target cells. Binding enables access to the appropriate cellular compartment so that the knowledge of the receptor allows essential insight into the mechanism of these toxins. Unlike other bacterial protein toxins (such as the clostridial C1 and C2 toxins from C. botulinum), C3 exoenzyme is devoid of a binding and translocation domain, with which toxins usually initiate receptor-mediated endocytosis followed by access to the intact cell. To date, no specific mechanism for internalization of C3 exoenzyme has been identified. Recently, vimentin was identified as membranous C3-binding partner involved in binding and uptake of C3. Although vimentin is not detected in neurons, vimentin is re-expressed after damage in regenerating neurons. Reappearance of vimentin allows C3 to get access to lesioned neurons/axons to exhibit axonotrophic and dentritotrophic effects.
引用
收藏
页码:97 / 118
页数:22
相关论文
共 50 条
  • [1] Therapeutic effects of Clostridium botulinum C3 exoenzyme
    Ingo Just
    Astrid Rohrbeck
    Stefanie C. Huelsenbeck
    Markus Hoeltje
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 383 : 247 - 252
  • [2] Recognition of RhoA by Clostridium botulinum C3 exoenzyme
    Wilde, C
    Genth, H
    Aktories, K
    Just, I
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) : 16478 - 16483
  • [3] Therapeutic effects of Clostridium botulinum C3 exoenzyme
    Just, Ingo
    Rohrbeck, Astrid
    Huelsenbeck, Stefanie C.
    Hoeltje, Markus
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 (03) : 247 - 252
  • [4] Novel biological activity of Clostridium botulinum exoenzyme C3
    Ahnert-Hilger, G
    Hofmann, F
    Pickert, G
    Grosse, G
    Just, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R49 - R49
  • [5] Role of vimentin in uptake of Clostridium botulinum C3 exoenzyme
    Rohrbeck, A.
    Hagemann, S.
    Pich, A.
    Hoeltje, M.
    Ahnert-Hilger, G.
    Just, I.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S48 - S48
  • [6] Binding of Clostridium botulinum C3 exoenzyme to intact cells
    Astrid Rohrbeck
    Leonie von Elsner
    Sandra Hagemann
    Ingo Just
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387 : 523 - 532
  • [7] Binding of Clostridium botulinum C3 exoenzyme to intact cells
    Rohrbeck, Astrid
    von Elsner, Leonie
    Hagemann, Sandra
    Just, Ingo
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2014, 387 (06) : 523 - 532
  • [8] C3 exoenzyme of Clostridium botulinum alters the proteome of hippocampal cells
    Schroeder, A.
    Rohrbeck, A.
    Just, I
    Pich, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 : 98 - 98
  • [9] Binding of Clostridium botulinum C3 exoenzyme to intact cells.
    Rohrbeck, Astrid
    von Elsner, Leonie
    Hagemann, Sandra
    Just, Ingo
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2014, 387 : S79 - S79
  • [10] Vimentin and integrin are involved in uptake of Clostridium botulinum C3 exoenzyme
    Wehmeyer, J. C.
    Hagemann, S.
    Rohrbeck, A.
    Just, I.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (SUPPL 1) : 83 - 83